A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
Condition: Non-Muscle Invasive Bladder Neoplasms · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (123)
| Arkansas Urology | Little Rock, Arkansas, United States | — |
| Genesis Research LLC 1 | Los Alamitos, California, United States | — |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| University of California Irvine Medical Center | Orange, California, United States | — |
| University of California San Francisco | San Francisco, California, United States | — |
| Genesis Research LLC | Torrance, California, United States | — |
| Colorado Clinical Research | Lakewood, Colorado, United States | — |
| Florida Urology Partners | Riverview, Florida, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| UroPartners | Chicago Ridge, Illinois, United States | — |
| Urology of Indiana | Carmel, Indiana, United States | — |
| First Urology, PSC | Jeffersonville, Indiana, United States | — |
+ 111 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06211764